Minoru Fukuda

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 17

Top Venues

Thoracic cancer

Cancer medicine

Cancer chemotherapy and pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Hiromi Tomono, Hirokazu Taniguchi, Minoru Fukuda, Takaya Ikeda, Seiji Nagashima, Kazumasa Akagi, Sawana Ono, Yasuhiro Umeyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto, Yasushi Hisamatsu, Ryotaro Morinaga, Ryuta Tagawa, Ryosuke Ogata, Yosuke Dotsu, Hiroaki Senju, Hiroshi Soda, Katsumi Nakatomi, Fumiko Hayashi, Nanae Sugasaki, Akitoshi Kinoshita, Hiroshi Mukae
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study. Thoracic cancer (2023)
Kazumasa Akagi, Hirokazu Taniguchi, Minoru Fukuda, Takuya Yamazaki, Sawana Ono, Hiromi Tomono, Takayuki Suyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Yosuke Dotsu, Hiroaki Senju, Hiroshi Soda, Takashi Mizowaki, Yoshio Monzen, Takaya Ikeda, Seiji Nagashima, Yutaro Tasaki, Daisuke Nakamura, Kazutoshi Komiya, Katsumi Nakatomi, Eisuke Sasaki, Koichi Hirakawa, Hiroshi Mukae
Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-disease small cell lung cancer: protocol of ACIST study. Thoracic cancer 13 (16) (2022)
Minoru Fukuda, Masafumi Yamaguchi, Takuya Yamazaki, Soichiro Funaki, Hiroshi Mukae, Junya Fukuoka, Kazuki Nabeshima, Hisashi Tateyama, Kazuto Ashizawa, Noriyuki Tomiyama, Masaki Hara, Takashi Seto, Meinoshin Okumura, Kenji Sugio
Phase II study of S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Results of the LOGIK1605/JART-1501 study. Thoracic cancer 13 (17) (2022)
Hirokazu Taniguchi, Shinnosuke Takemoto, Mutsumi Ozasa, Noritaka Honda, Takayuki Suyama, Yasuhiro Umeyama, Yosuke Dotsu, Takumi Nakao, Kojima Tomohito, Hiroshi Gyotoku, Hiroyuki Yamaguchi, Taiga Miyazaki, Noriho Sakamoto, Yasushi Obase, Minoru Fukuda, Junya Fukuoka, Hiroshi Mukae
Remarkable response to pembrolizumab with platinum-doublet in PD-L1-low pulmonary sarcomatoid carcinoma: A case report. Thoracic cancer 12 (7) (2021)
Naoko Sueoka-Aragane, Chiho Nakashima, Hironori Yoshida, Naohisa Matsumoto, Kentaro Iwanaga, Noriyuki Ebi, Akihiro Nishiyama, Kazuhiro Yatera, Shoichi Kuyama, Minoru Fukuda, Sunao Ushijima, Hitomi Umeguchi, Daijiro Harada, Kosuke Kashiwabara, Takayuki Suetsugu, Nobukazu Fujimoto, Fumihiro Tanaka, Hidetaka Uramoto, Chiharu Yoshii, Katsumi Nakatomi, Genju Koh, Nobuhiko Seki, Keisuke Aoe, Kaname Nosaki, Koji Inoue, Ayako Takamori, Atsushi Kawaguchi
The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment. Cancer medicine 10 (12) (2021)
Shinnosuke Takemoto, Kazumasa Akagi, Sawana Ono, Hiromi Tomono, Noritaka Honda, Takayuki Suyama, Yasuhiro Umeyama, Yosuke Dotsu, Hirokazu Taniguchi, Daiki Ogawara, Hiroaki Senju, Hiroshi Gyotoku, Nanae Sugasaki, Hiroyuki Yamaguchi, Katsumi Nakatomi, Minoru Fukuda, Hiroshi Mukae
Efficacy of S-1 after pemetrexed in patients with non-small cell lung cancer: A retrospective multi-institutional analysis. Thoracic cancer 12 (17) (2021)
Takaya Ikeda, Shinnosuke Takemoto, Hiroaki Senju, Hiroshi Gyotoku, Hirokazu Taniguchi, Midori Shimada, Yosuke Dotsu, Yasuhiro Umeyama, Hiromi Tomono, Takeshi Kitazaki, Masaaki Fukuda, Hiroshi Soda, Hiroyuki Yamaguchi, Minoru Fukuda, Hiroshi Mukae
Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study. Thoracic cancer 11 (7) (2020)
Yosuke Dotsu, Minoru Fukuda, Noritaka Honda, Hiroshi Gyotoku, Yoshihisa Kohno, Takayuki Suyama, Yasuhiro Umeyama, Hirokazu Taniguchi, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Taiga Miyazaki, Noriho Sakamoto, Yasushi Obase, Hiroaki Ikeda, Kazuto Ashizawa, Hiroshi Mukae
Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation. Thoracic cancer 12 (2) (2020)
Minoru Fukuda, Soichiro Funaki, Takuya Yamazaki, Shuntaro Sato, Hiroshi Mukae, Mitsuhiro Takenoyama, Junya Fukuoka, Kazuki Nabeshima, Hisashi Tateyama, Kazuto Ashizawa, Masaki Hara, Takashi Seto, Meinoshin Okumura, Kenji Sugio
S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART-1501. Thoracic cancer 11 (3) (2020)
Shinnosuke Takemoto, Yoichi Nakamura, Hiroshi Gyoutoku, Hiroaki Senju, Daiki Ogawara, Takaya Ikeda, Hiroyuki Yamaguchi, Takeshi Kitazaki, Hirofumi Nakano, Katsumi Nakatomi, Shinya Tomari, Shuntaro Sato, Seiji Nagashima, Minoru Fukuda, Hiroshi Mukae
Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA. Thoracic cancer 10 (3) (2019)
Hirokazu Taniguchi, Hiroyuki Yamaguchi, Yosuke Dotsu, Midori Shimada, Hiroshi Gyotoku, Hiroaki Senju, Shinnosuke Takemoto, Takeshi Kitazaki, Masaaki Fukuda, Daiki Ogawara, Hiroshi Soda, Katsumi Nakatomi, Nanae Sugasaki, Akitoshi Kinoshita, Seiji Nagashima, Takaya Ikeda, Yoichi Nakamura, Noriho Sakamoto, Yasushi Obase, Minoru Fukuda, Hiroshi Mukae
Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer. Thoracic cancer 10 (9) (2019)
Mio Mori, Hideyuki Hayashi, Minoru Fukuda, Sumihisa Honda, Takeshi Kitazaki, Kazuto Shigematsu, Naohiro Matsuyama, Mayumi Otsubo, Takeshi Nagayasu, Mikiko Hashisako, Kazuhiro Tabata, Masataka Uetani, Kazuto Ashizawa
Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR-negative lung cancer. Thoracic cancer 10 (4) (2019)
Shinnosuke Takemoto, Minoru Fukuda, Hiroyuki Yamaguchi, Takaya Ikeda, Kazumasa Akagi, Hiromi Tomono, Yasuhiro Umeyama, Yosuke Dotsu, Hirokazu Taniguchi, Hiroshi Gyotoku, Hiroaki Senju, Takeshi Kitazaki, Katsumi Nakatomi, Seiji Nagashima, Masaaki Fukuda, Akitoshi Kinoshita, Hiroshi Soda, Hiroshi Mukae
Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study. Thoracic cancer 11 (2) (2019)
Midori Shimada, Hiroyuki Yamaguchi, Minoru Fukuda, Hiromi Tomono, Noritaka Honda, Yosuke Dotsu, Hirokazu Taniguchi, Hiroshi Gyotoku, Hiroaki Senju, Shinnosuke Takemoto, Takaya Ikeda, Katsumi Nakatomi, Yoichi Nakamura, Seiji Nagashima, Takuya Yamazaki, Hiroshi Mukae
Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer. Cancer chemotherapy and pharmacology 84 (5) (2019)
Takaya Ikeda, Hiroyuki Yamaguchi, Yosuke Dotsu, Hirokazu Taniguchi, Hiroshi Gyoutoku, Hiroaki Senju, Noriho Sakamoto, Satoshi Iwanaga, Yutaka Kuwatsuka, Minoru Fukuda, Hiroshi Mukae
Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma. Thoracic cancer 9 (11) (2018)
Kazuaki Okamura, Yuichi Fukuda, Hiroshi Soda, Daiki Ogawara, Keisuke Iwasaki, Shinichiro Fuchi, Takayuki Suyama, Masataka Yoshida, Tatsuhiko Harada, Minoru Fukuda, Hiroshi Mukae
Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab. Thoracic cancer 9 (1) (2017)
Minoru Fukuda, Manabu Okumura, Tomomi Iwakiri, Kazuhiko Arimori, Takuya Honda, Kazuma Kobayashi, Hiroaki Senju, Shinnosuke Takemoto, Takaya Ikeda, Hiroyuki Yamaguchi, Katsumi Nakatomi, Nobuko Matsuo, Hiroshi Mukae, Kazuto Ashizawa
Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer. Thoracic cancer 9 (1) (2017)

Minoru Fukuda.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Minoru Fukuda